Researchers have reported highly encouraging results from a major international clinical trial evaluating a personalized mRNA cancer vaccine for melanoma patients. The treatment was used alongside immunotherapy and demonstrated a 42% reduction in the risk of cancer returning or resulting in death compared with immunotherapy alone.
Scientists create the vaccine by analyzing each patient’s tumor and identifying unique mutations. Advanced AI tools help select targets that train the immune system to recognize and destroy remaining cancer cells. Experts describe the findings as one of the most significant advances in cancer immunotherapy in recent years.
About the Author
